Nanobiotechnology Under Pressure to Justify the Enormous Private and Public Funding it has Received

Aug 30, 2005, 01:00 ET from Frost & Sullivan

    LONDON, August 30 /PRNewswire/ -- Nanotechnology has received as much
 media attention than any other science sector since the space race of the
 1960s. This hype has attracted large sums of 'reactionary' public and venture
 capital funding, and has brought in its wake tremendous pressure on market
 participants to deliver results.
     The onus is now on participants in the nanobiotechnology applications
 sector to incorporate extensively researched technologies into commercially
 viable products.
     New analysis from Frost & Sullivan (, World
 Nanobiotechnology Market, reveals that Sales of nanomaterials for use in
 nanobiotechnology applications generated revenues of USD 750.0 million in
 2004. This figure is projected to reach USD 2,056.5 million in 2011.
     Nanobiotechnology deals with nanomaterials and their applications in life
 sciences. Breakthrough applications in nano-scale therapeutics, drug delivery
 systems, and nano-scale scaffolds for tissue reconstruction are surfacing
 from laboratories into the development phase.
     "Industry participants need to focus on collaborating well with
 interdisciplinary research partners to ensure sustainable growth of this
 emerging market," says Frost & Sullivan Industry Analyst Phil Webster.
     Such enterprising market strategies are the need of the hour, since many
 alternative technologies are posing a significant challenge to the
 nanobiotechnology sector. Conventional therapeutics, liposomes, and
 monoclonal antibodies are all established therapies and already have
 regulatory compliance and case law in place, unlike nanobiotechnology, which
 gives them a competitive edge.
     As an emerging segment, nanobiotechnology holds great potential in the
 treatment of neurological disorders and cancer, which are areas of unmet
 medical need.
     Most nanobiotechnology products that have satisfied regulatory
 requirements to date are cosmetics and medicinal creams, which use metallic
 nanoparticles to improve absorption. Reformulated compounds that use
 nanoemulsion delivery systems have gained legislative approval and are
 commercially available. In February 2005, the first nanoparticulate
 therapeutic reached the market, a major step in the development of the
 nanobiotechnology market. With improving regulatory climate, market
 participants are drawing up plans for novel nanobiotechnology products.
     While devising new applications for nanobiotechnology, competing
 companies will have to take into account the costs of nanomaterials. Since
 nanomaterials have not generated much demand owing to the small quantities in
 which they are required, it is unfeasible to establish large-scale automated
 manufacturing systems.
     Reactionary funding is proving essential to the establishment of the
 nanobiotechnology market. Significant public and private investment in
 nanobiotechnology are sponsoring research projects in academia and
 facilitating the establishment of start-up and spin-off companies for
 commercialising nanobiotechnology applications.
     "The funds have been used to set up sound infrastructure, particularly in
 the United States and Europe, for small companies to network and
 collaborate," says Mr Webster. "It is essential for industry participants to
 be aware of what funding sources are available and where, as this indicates
 hot spots of business opportunity."
     The World Nanobiotechnology Market, part of the Biotechnology
 subscription, research service specifically focuses on nanobiotechnology
 rather than visualisation and diagnostics applications. It analyses
 nanomaterial markets specific to the nanobiotechnology sector as well as
 application of these nanomaterials in pure therapeutics, drug delivery
 systems, and tissue reconstruction. Interviews are available to the press.
     If you are interested in an analysis overview, which provides
 manufacturers, end users, and other industry participants with a synopsis,
 summary, advantages and disadvantages of the World Nanobiotechnology Market
 (F289) - then send an e-mail to Katja Feick - Corporate Communications at with the following information: your full name, company
 name, title, telephone number, e-mail address, city, state and country. We
 will send you the information via e-mail upon receipt of the above
     World Nanobiotechnology Market (F289)
     Frost & Sullivan, a global growth consulting company, has been partnering
 with clients to support the development of innovative strategies for more
 than 40 years. The company's industry expertise integrates growth consulting,
 growth partnership services and corporate management training to identify and
 develop opportunities. Frost & Sullivan serves an extensive clientele that
 includes Global 1000 companies, emerging companies, and the investment
 community, by providing comprehensive industry coverage that reflects a
 unique global perspective and combines ongoing analysis of markets,
 technologies, econometrics, and demographics.
     Media Contacts:
     Katja Feick
     Corporate Communications
     P: +44(0)20-7915-7856
     F: +44(0)20-7730-3343
     Melina Trevino
     Corporate Communications
     P: +1-210-247-2440
     F: +1-210-348-1003
     Radhika Menon Theodore
     Corporate Communications
     P: +91-44-24314263 Ext: 312
     Surbhi Dedhia
     Corporate Communications
     P: +91-22-2832-4705 Ext: 131
     Sharmin Jassal
     Corporate Communications
     P: + 61-2-8247-8900
     F: + 61-2-9252-8066
     Keywords in this release: Computational biology tools, drug discovery,
 biology, U.S., Food and Drug Administration, FDA, homology mapping,
 deoxyribonucleic acid microarray, DNA, computer-aided molecular design,
 ultrahigh throughput system, HTS, ultra HTS, uHTS, research, information,
 market, trends, technology, service, forecast, market share

SOURCE Frost & Sullivan